ZYXEL-COMMUNICATIONS
13.1.2021 07:02:39 CET | Business Wire | Press release
Telenor Norway has selected Zyxel Communications’ 5G NR Fixed Wireless Access outdoor router – NR 7101 to roll out the world’s fastest and biggest 5G FWA.
As the first mobile operator of 5G in Scandinavia, Telenor is modernizing its existing network infrastructure with plans to offer nationwide 5G access by 2024. The company introduced wireless broadband in May 2019. Later that year, Telenor Norway partnered with Ericsson to modernize and deliver its nationwide 5G radio access network.
The selection of Zyxel Communications marks yet another important milestone for Telenor’s work in upgrading customers to 5G.
Zyxel’s 5G NR FWA outdoor router – NR 7101 uses modern antenna technology for Telenor to offer high-speed wireless connectivity. The company cited Zyxel’s innovative technology, effective local presence and collaborative approach as key reasons for its decision.
“Telenor is dedicated to providing Individual customers and businesses with faster speeds and more bandwidth,” said Camilla Amundsen, CMO, Fixed and TV of Telenor Norway. “Customers connect more innovative technologies and smart devices to their respective networks and expect maximum coverage everywhere. FWA supports the increasing number of individuals and families working and learning from home; where platforms such as video conferences, interactive learning, cloud-based enterprise solutions, TV streaming and online gaming demand significant broadband access. FWA is therefore an important part of Telenor’s network modernization and our partnership with Zyxel makes this possible.”
“Zyxel is helping Telenor reach an additional level of service for customers throughout Norway and oversee the world’s fastest, largest rollout of 5G FWA,” Amundsen added.
With Zyxel’s NR7101 outdoor router, Telenor also will provide customers with a smooth transition to 5G, while offering them access to its 4G network. This allows the provider to maximize speeds, regardless of network, and leverage its existing infrastructure investments throughout the rollout of 5G.
“Telenor is an industry pioneer in 5G and is at the forefront of deploying modern, next-generation networks for customers,” said Karsten Gewecke, SVP, Head of EMEA Regional BU at Zyxel Communications. “With our state-of-the-art 5G NR FWA technology, we’re playing a major role in delivering superior wireless access to customers everywhere throughout Norway.”
“Combined with short delivery time, high speeds and increased reliability, FWA is an attractive solution for many customers – not only existing DSL customers,” Karsten Gewecke concludes.
Telenor currently offers 5G in the following areas: Trondheim, Bergen, Kongsberg, Elverum, Bodø, Askvoll, Telenor Fornebu, Kvitfjell, Longyearbyen, Herøya, Frøya and Spikersuppa in Oslo. The service provider also is actively deploying 5G in Ålesund, Kristiansand, Fredrikstad, Tromsø and Bodø. In addition, Telenor plans to make 5G available nationwide in Norway by 2024. Likewise, after December 2020, all new FWA-customers are offered Zyxel’s 5G-ready FWA outdoor router, which ensures a smooth transition for subscribers not yet covered by 5G.
About Telenor Norway
Telenor Norway AS is the country's largest provider of telecommunications and digital services. Its infrastructure is the foundation of the digitization of Norway with world-class coverage and speeds. Its services and products contribute to increased productivity and provide access to all digital content. Its safety and emergency response organization works 24/7 to keep customers safe, and Telenor Norway takes special social responsibility to create safety for children and young people online.
About Zyxel Communications
Zyxel Communications delivers technological innovations and has connected the world to the Internet for more than 30 years. Whether it’s a matter of establishing access through fixed or mobile broadband solutions, Zyxel Communications offers a comprehensive and flexible portfolio of products that’s keeping service providers ahead of the competition.
Read the full Telenor customer story here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112006083/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom